News >

Durvalumab Has Emerging Role in Head and Neck Cancer

Danielle Bucco
Published: Tuesday, Oct 24, 2017

Daniel Zandberg, MD

Daniel Zandberg, MD
PD-1/PD-L1 inhibitors continue to play an important part in the treatment paradigm for patients with head and neck cancer, as ongoing clinical trials are exploring additional agents.

, Dan Zandberg, MD, an assistant professor at the University of Maryland School of Medicine, discussed results from the HAWK study as well as current combination approaches for patients with head and neck cancer.

OncLive: Can you please summarize the results of the HAWK trial?

Zandberg: The HAWK trial is a phase II trial in recurrent metastatic head and neck cancer for patients who had PD-L1–high expression, defined as greater than 25% tumor cell expression. Promising outcomes were observed. The ORR was 16% with durable responses seen, with 55% ongoing at data cutpoint. The median OS was 7 months with a 1-year survival of 33%.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication